Rock Springs Capital Management LP Makes New $4.86 Million Investment in Stryker Corporation $SYK

Rock Springs Capital Management LP purchased a new position in Stryker Corporation (NYSE:SYK) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,800 shares of the medical technology company’s stock, valued at approximately $4,863,000.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after buying an additional 133,892 shares during the last quarter. State Street Corp grew its holdings in Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after acquiring an additional 311,507 shares during the period. Geode Capital Management LLC raised its position in shares of Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after acquiring an additional 69,851 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Finally, Norges Bank acquired a new position in shares of Stryker in the 4th quarter valued at about $1,822,272,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Shares of SYK opened at $337.31 on Tuesday. The company has a market capitalization of $129.31 billion, a price-to-earnings ratio of 39.04, a PEG ratio of 2.12 and a beta of 0.77. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.14. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average of $315.18 and a 200 day moving average of $335.37.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the firm posted $2.84 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent analyst reports. Citigroup decreased their target price on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Canaccord Genuity Group cut their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Argus set a $370.00 price objective on shares of Stryker in a research report on Thursday, July 9th. Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. Finally, Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $392.52.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.